Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03770312 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.
This record was last updated November 18, 2025 (before its estimated January 16, 2026 completion). Its status may not reflect the trial's current state.
NotableTrial status: Not Yet Recruiting to Recruitingv7Show 6 more changesShow less
Enrollment target: 2484 to 724
Eligibility criteria expanded, about 139 words
Secondary endpoints: details revised at 1 of 1 entry
Study description expanded, about 33 words
Site details revised
Study title revised
NotableTrial status: Terminated to Not Yet Recruitingv6Show 6 more changesShow less
Enrollment target: 14 to 2484
Primary and study completion dates: Aug 14, 2019 to Jan 16, 2026
Start date: Apr 16, 2019 to Mar 5, 2020
Eligibility criteria expanded, about 28 words
Secondary endpoints: details revised at 1 of 1 entry
Site contact updated
StoppedTrial status: Recruiting to TerminatedSponsor's reason: It was needed to change the study design, and further progress was impossible.
In this regard, we decided to terminate the study.
Enrollment target: estimated 2234 to confirmed 14
Primary and study completion dates changed from estimate of Aug 15, 2024 to Aug 14, 2019
Site details revised
v5
NotableTrial status: Not Yet Recruiting to Recruiting
Start date changed from estimate of Mar 2019 to Apr 16, 2019
Site details revised
v4
MinorStart date: Jan 2019 to Mar 2019v3
MinorStart date: Dec 10, 2018 to Jan 2019v2
MinorStudy First Submitted
Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
One of the most effective drug in the primary prevention of cardiovascular disease is statins. The protective effects of statin on developement of cardiovascular disease has been demonstrated in elderly individuals. Since side effects of statin are more common in elderly individuals than in younger individuals, clinical guidelines recommend that use of low intensity statin is considered in elderly individuals. However, there are few randomized clinical trials evaluating the safety and efficacy of different intensity statins in elderly individuals.
This is a multicenter, prospective, randomized clinical trial to compare efficacy and safety between low and high intensity statin for primary prevention of cardiovacsular disease in elderly individuals.